Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a dose-ranging study of PTC518 in Huntington's disease
2023-509835-26-00Phase 2Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in Huntington disease (HD) comparing PTC518 with Placebo (2 arms). Primary endpoints: Safety profile and Change from baseline in blood total huntingtin protein. Started May 2024; status: completed.
02
Drugs
votoplam
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2023-509835-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509835-26-00.